Publicaciones científicas
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
J A Ledermann 1 , X Matias-Guiu 2 , F Amant 3 , N Concin 4 , B Davidson 5 , C Fotopoulou 6 , A González-Martin 7 , C Gourley 8 , A Leary 9 , D Lorusso 10 , S Banerjee 11 , L Chiva 12 , D Cibula 13 , N Colombo 14 , S Croce 15 , A G Eriksson 16 , C Falandry 17 , D Fischerova 13 , P Harter 18 , F Joly 19 , C Lazaro 20 , C Lok 21 , S Mahner 22 , F Marmé 23 , C Marth 24 , W G McCluggage 25 , I A McNeish 6 , P Morice 26 , S Nicum 27 , A Oaknin 28 , J A Pérez-Fidalgo 29 , S Pignata 30 , P T Ramirez 31 , I Ray-Coquard 32 , I Romero 33 , G Scambia 10 , J Sehouli 34 , R Shapira-Frommer 35 , S Sundar 36 , D S P Tan 37 , C Taskiran 38 , W J van Driel 21 , I Vergote 39 , F Planchamp 40 , C Sessa 41 , A Fagotti 42
Abstract
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain.
The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer.
Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise.
Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.
CITA DEL ARTÍCULO Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7.doi: 10.1016/j.annonc.2023.11.015
Nuestros autores
